Synonym
PD 117519; PD117519; PD-117519
IUPAC/Chemical Name
N-[(1R)-2,3-dihydro-1H-inden-1-yl]-adenosine
InChi Key
FSKMJUWPFLDDRS-BYMDKACISA-N
InChi Code
InChI=1S/C19H21N5O4/c25-7-13-15(26)16(27)19(28-13)24-9-22-14-17(20-8-21-18(14)24)23-12-6-5-10-3-1-2-4-11(10)12/h1-4,8-9,12-13,15-16,19,25-27H,5-7H2,(H,20,21,23)/t12-,13-,15-,16-,19-/m1/s1
SMILES Code
OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C(N=CN=C32)N[C@@H]4CCC5=C4C=CC=C5)O1)O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
PD 117519 is an adenosine receptor agonist that selectively binds to adenosine A2 receptors.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
10.0 |
26.08 |
| DMF:PBS (pH 7.2) (1:4) |
0.2 |
0.52 |
| DMSO |
52.5 |
136.93 |
| Ethanol |
0.1 |
0.26 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
383.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Tobin GA, Zhang J, Goodwin D, Stewart S, Xu L, Knapton A, González C, Bancos S, Zhang L, Lawton MP, Enerson BE, Weaver JL. The role of eNOS phosphorylation in causing drug-induced vascular injury. Toxicol Pathol. 2014 Jun;42(4):709-24. doi: 10.1177/0192623314522885. Epub 2014 Apr 3. PMID: 24705881.
2: Enerson BE, Lin A, Lu B, Zhao H, Lawton MP, Floyd E. Acute drug-induced vascular injury in beagle dogs: pathology and correlating genomic expression. Toxicol Pathol. 2006;34(1):27-32. doi: 10.1080/01926230500512068. PMID: 16507541.
3: Albassam MA, Smith GS, Macallum GE. Arteriopathy induced by an adenosine agonist-antihypertensive in monkeys. Toxicol Pathol. 1998 May-Jun;26(3):375-80. doi: 10.1177/019262339802600311. PMID: 9608643.
4: Reynolds DL, Pachla LA. Liquid chromatographic analysis of the adenosine agonist PD 117519 in dog plasma. J Pharm Biomed Anal. 1991;9(4):345-9. doi: 10.1016/0731-7085(91)80204-m. PMID: 1911988.
5: Metz AL, Dominick MA, Suchanek G, Gough AW. Acute cardiovascular toxicity induced by an adenosine agonist-antihypertensive in beagles. Toxicol Pathol. 1991;19(2):98-107. doi: 10.1177/019262339101900203. PMID: 1771371.
